Latvija - latviešu - Zāļu valsts aģentūra

b.braun melsungen ag, germany - isoleucinum, leucinum, lysini hydrochloridum, methioninum, phenylalaninum, threoninum, tryptophanum, valinum, argininum, histidinum, alaninum, glycinum, skābes asparticum, skābes glutamicum, prolinum, serinum, tyrosinum, natrii acetas trihydricus, natrii hydroxidum, kalii acetas, magnija chloridum hexahydricum, dinatrii phosphas dodecahydricus - Šķīdums infūzijām - 10%

Latvija - latviešu - Zāļu valsts aģentūra

b.braun melsungen ag, germany - isoleucinum, leucinum, lysini monohydricum, lysini acetas, methioninum, phenylalaninum, threoninum, tryptophanum, valinum, argininum, histidinum, alaninum, glycinum, skābes asparticum, skābes glutamicum, prolinum, serinum, tyrosinum - Šķīdums infūzijām - 10%

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

bela-pharm gmbh&co.kg, vācija - lincomycin hydrochloride monohydrate, spectinomycin sulphate tetrahydrate - šķīdums injekcijām - cūkas; kaķi; suņi; teļi

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae celms ms-h - immunologicals par aves, dzīvu baktēriju vakcīnas - cālis - aktīvās imunizācijas nākotnes broileru vistu audzētājs, nākotnē slāni audzētājs vistas un turpmāko kārtu vistas, lai samazinātu gaisa sac bojājumi, un samazināt uz olām, ar neparastu čaumalas veidošanos, ko izraisa mikoplazmas synoviae.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cūkas - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zoetis belgium s.a., beļģija - mycoplasma hyopneumoniae - suspensija injekcijām - cūkas

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

bioveta, a.s., Čehija - poxvirus myxomatosae attenuatum - liofilizāts un šķīdinātājs šķīduma injekcijām pagatavošanai - truši

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

intervet international b.v. - cūku circovirus tips 2 (pcv2) orf2 apakšvienības antigēnu, mycoplasma hyopneumoniae j celma inaktivēta - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cūkas (nobarošanas) - aktīvās imunizācijas cūkām, lai samazinātu virēmija, vīrusu slodze plaušām un limfoīdo audu, vīrusu izplatīšanos izraisa cūku circovirus tips 2 (pcv2) infekcija, un smaguma plaušu bojājumi, ko izraisa mycoplasma hyopneumoniae infekcija. lai samazinātu ikdienas svara pieauguma zudumu beigu periodā, saskaroties ar mycoplasma hyopneumoniae un / vai pcv2 infekcijām (kā novēroti lauka pētījumos).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunoloģiskie līdzekļi suidae - cūkas (nobarošanas) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

bela-pharm gmbh&co.kg, vācija - kalcija pantotenāts,pyridoxine hydrochloride,riboflavine nātrija fosfāts,tiamīna hidrohlorīds,nikotīnamīds - šķīdums injekcijām - cūkas; govis; kaķi; lapsas; suņi; zirgi; ūdeles